"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Pembrolizumab (Keytruda) for adjuvant treatment of Melanoma Patients

25 Feb 2019 10:54 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software